WO1995005840A1 - Periodontal disease remedy - Google Patents
Periodontal disease remedy Download PDFInfo
- Publication number
- WO1995005840A1 WO1995005840A1 PCT/JP1993/001211 JP9301211W WO9505840A1 WO 1995005840 A1 WO1995005840 A1 WO 1995005840A1 JP 9301211 W JP9301211 W JP 9301211W WO 9505840 A1 WO9505840 A1 WO 9505840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- periodontal tissue
- tissue disease
- therapeutic agent
- growth factor
- periodontal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
Definitions
- the present invention relates to a therapeutic agent for periodontal tissue disease containing basic fibroblast growth factor as an active ingredient, and a method for treating periodontal tissue disease using the same. More specifically, diseases such as periodontal ligament, alveolar bone and cement, which are the ultimate goal of treatment, are regenerative healing or neoadhesion healing.
- the present invention relates to drugs used for the purpose of guiding patients and methods of treatment using the same.
- periodontitis is mainly caused by the formation of colonies on the root surface. Therefore, the emphasis is mainly on removing plaques and marks mechanically attached to the tooth surface by scaling, and keeping the state of the flakes free. Is placed.
- periodontal surgery for severe periodontitis also involves treatment of plaque and calculus that have adhered to the root surface in the periodontal box.
- O has been designed to improve the environment for more effective oral cleaning by removing causative factors and pathological tissues.
- chemotherapy with antibiotics has been attempted in addition to these therapies. ⁇
- Regenerative healing refers to the regeneration of alveolar bone as well as the formation of cement (collagen healing) in which collagen fibers are embedded in the root surface exposed after surgery. Healing in the form of healing.
- reattachment refers to a healing form in which a long epithelial attachment observed on the root surface or a collagen fiber bundle that does not require functional recovery is accumulated on the root surface. It is.
- the present invention relates to a therapeutic agent for periodontal tissue disease excellent in safety and efficacy, a method for treating periodontal tissue disease using the same, and an agent for promoting implantation of implant material. Further, the present invention aims to provide a dentin regeneration treatment agent. Disclosure of the invention
- the present invention relates to a therapeutic agent for periodontal tissue disease, comprising a basic fibroblast growth factor as an active ingredient.
- bFGF basic fibroblast growth factor
- a mutein in which a part of the amino acid is replaced by another amino acid or a part of the amino acid is deleted, and acts as a fibroblast growth factor. O They may be used alone or as a mixture thereof o
- W087 / 01728 Japanese Patent Publication No. Sho 63-500843
- W089 / 048 3 2 Japanese Patent Application Laid-open No. Sho 63-35001953
- European Patent Application Publication No. Official Gazette European Patent Application Publication No. 281822
- European Patent Application Publication No. 281822 Japanese Patent Application Laid-Open No. Hei 21-193
- a polypeptide having 154 amino acid sequences of SEQ ID NO: 1 produced by the genetic engineering method described in W087017272 Riptide and SEQ ID NO: 2
- Polypeptides with a sequence of 153 amino acids are said to be easy to provide consistently and consistently in the required quantity. This is especially favorable.
- it was prepared from human kidney mRNA as described in Examples of JP-T- 63-500843 ; lgt10c DNA. From the library, a human basic FGF cDNA clone was prepared using the 1.4 kb basic subfragment of the yeast, and an expression vector was constructed. By expressing lone, a polypeptide having 154 amino acid sequences of SEQ ID NO: 1 can be obtained by using a genetic engineering technique. .
- peripheral tissue refers to the tissue around the tooth, which is a supporting device for the tooth, and has periodontal ligament, alveolar bone, cement, gingiva, and oral cavity. It means a tissue composed of mucous membranes.
- the periodontal ligament is a connective tissue that connects the teeth to the alveolar fossa, usually about 200 to 250 jum in thickness, and the occlusal force etc. directly affects the alveolar bone. It has a buffering action to prevent it. For this reason, the periodontal ligament is composed of a group of fibers (sharp fibers) that connect the teeth to the alveolar bone, and abundantly distributed lymphatic vessels, blood vessels, and nerves. It protects the teeth and periodontal tissue from the nutrition and strong impact of the skin. Cell components include fibroblasts, cementoblasts, and osteoblasts.
- Alveolar bone means the jaw bone that supports the teeth through the periodontal ligament.
- the alveolar bone plays a role as a supporting organ while repeating remodeling.
- periodontal tissue diseases such as periodontitis
- the alveolar bone is remodeled. Disruption of the ring balance can lead to bone resorption with changes in osteoblasts and osteoclasts.
- cementum is a light yellow bone-like connective tissue that covers the periphery of the tooth root, and embeds the sharp fibers of the periodontal ligament to connect the alveolar bone and the teeth. Means an organization. Since the cement is nourished by the periodontal ligament, it becomes necrotic with the loss of the periodontal ligament and becomes foreign after infection.
- the therapeutic agent for periodontal tissue disease of the present invention has an excellent regeneration promoting action on periodontal tissues such as cement, periodontal ligament and alveolar bone. Not only does the periodontal tissue lost or damaged by the progress of the flame lead to regenerative healing or new adhesion healing, which is the final goal of treatment, but also to related diseases Affected dentin, for example, after tooth extraction and cyst or oral cancer removal, restoration of periodontal tissue, promotion of implantation of implant material, and touch. It is effective for the regeneration of dentistry and is used for various periodontal disease treatments.
- the therapeutic agent for periodontal tissue disease of the present invention may be prepared by adding bFGF to a pharmacologically acceptable additive, for example, a solvent, an isotonic agent, an emulsifier, Liquids, emulsions, gelling agents, powders, lyophilized formulations, microcapsules or mitoskins in combination with agents, stabilizers or fillers used in the dental field It can be prepared into a dosage form such as a cross-hair preparation.
- a pharmacologically acceptable additive for example, a solvent, an isotonic agent, an emulsifier, Liquids, emulsions, gelling agents, powders, lyophilized formulations, microcapsules or mitoskins in combination with agents, stabilizers or fillers used in the dental field It can be prepared into a dosage form such as a cross-hair preparation.
- a sustained-release preparation can be prepared according to the purpose.
- a method for incorporating bFGF into a therapeutic agent for periodontal tissue disease a known method such as mixing, kneading, dissolving, dipping, penetrating, spraying, and injecting is appropriately selected.
- the pH is preferably 4.0 to 8.0, particularly preferably 4.5 to 7.0 in consideration of the stability of FGF.
- the temperature should be 30 ° C, especially below 15 ° C It is preferable to control the time.
- the bFGF prepared in the above dosage form can be administered in the form of an external preparation, injection, patch, liniment, injection, implant, or the like.
- the content of bFGF in the preparation is preferably 0.0001 to 20%, and the amount of the additive other than the active ingredient used is 80 to 99.9999. % Is preferred.
- the bFGF to be administered may be prepared so as to contain 0.1 to: LOOO / ig, preferably 1 to 500 ⁇ g.
- the therapeutic agent for periodontal tissue disease of the present invention has a diseased part of periodontal disease and a root surface, exfoliated gingival surface and alveolar bone surface after tooth extraction, periodontal surgery or smooth surface lubrication treatment. Can be used by administering it to the vicinity.
- the form, symptom, and administration of the site to be administered should be administered to or near the affected area, or the like, of bFGF prepared in the above-mentioned dosage form. This is accomplished by administering the drug in an appropriate dosage form.
- the dose of the therapeutic agent can be appropriately increased or decreased depending on the symptom to be treated, the site, and the amount of FGF used per human.
- 0.1 to L; 0,000 // g, preferably l to 500 ⁇ g is applied to the affected area or its vicinity one to three times a day, the alveolar bone and root
- the effect of promoting regeneration of periodontal tissue such as membrane and cement is exhibited, and the desired therapeutic effect of periodontal tissue disease is exhibited.
- FIG. 1 shows an optical microscope of a pathological specimen obtained after a dog artificial periodontal tissue defect obtained by the periodontal tissue regeneration test in Example 1. It is a photograph.
- FIG. 2 is an optical micrograph of a ⁇ pathological specimen obtained after a surgical operation on a canine artificial periodontal tissue defect obtained by a periodontal tissue regeneration test of Comparative Example 1.
- FIG. 3 is an optical micrograph of a pathological specimen obtained two weeks after the operation of the dog artificial periodontal tissue defect obtained by the periodontal tissue regeneration test in Example 2.
- FIG. 4 is an optical microscopic photograph of a pathological specimen obtained two weeks after a dog artificial periodontal tissue defect operation obtained by a periodontal tissue regeneration test in Comparative Example 2.
- FIG. 5 is an optical microscopic photograph of a pathological specimen 4 weeks after the operation of the dog artificial periodontal tissue defect obtained by the periodontal tissue regeneration test in Example 2.
- FIG. 6 is an optical microscopic photograph of a pathological specimen 4 weeks after surgery for a canine artificial periodontal tissue defect obtained by a periodontal tissue regeneration test in Comparative Example 2.
- Fig. 7 shows the optical micrograph of a part of the pathological specimen 4 weeks after the operation of the artificial periodontal tissue defect in the dog, which was obtained by the periodontal tissue regeneration test in Example 2.
- the bFGF used in the following tests has a polyamino acid sequence having 154 amino acid sequences of SEQ ID NO: 1 produced by the genetic engineering method described in W087 / 0172828. It is a rebide.
- Formulation Example 1
- a saline solution was prepared by adding physiological saline to bFGF2.775 mg represented by SEQ ID NO: 1 so that the total amount was 0.555 ml.
- Example 1 The promotion of periodontal tissue regeneration was tested using the bFGF-containing solution.
- the test method and the results are shown below in Example 1 and Comparative Example 1.
- a healthy periodontal tissue was maintained by performing brushing and the like in the oral cavity of the beaded dog.
- the mucoperiosteal flap at the upper and lower left and right anterior teeth is peeled off to expose the bone according to the conventional method, and the bone is denuded through the alveolar bone and periodontal ligament from the ⁇ -side bone surface corresponding to the root of the tooth.
- An artificial periodontal tissue defect (diameter 3 mm, depth 2 mm) was created. The cementum was removed from the bottom of the defect using a chisel or the like, and dentin was exposed.
- Figure 1 shows the observation results of Example 1 and Figure 2 shows the observation results of Comparative Example 1. The results are shown. All were observed at a magnification of 10 times.
- Example 1 As shown in FIG. 1
- the periodontal ligament c formed between the new alveolar bone and the root surface is wider than the existing periodontal ligament, rich in capillaries, and its fibers (shear).
- the run of d was arranging obliquely or perpendicularly to the root surface of the tooth, and an image embedded in neonatal cement e was observed.
- the new cementum e is formed on the root surface that is exposed from the existing cementum surface, and the new cementum is also formed in the resorbable fossa of the dentin dentin.
- Example 2 Similar to Example 1, the new alveolar bone with osteoblasts b lined up to the trabecular margin from the alveolar bone cut section on the crown side (left side in Fig. 2) and apical side (right side in Fig. 2) Although a was seen to grow and penetrate toward the center of the defective cavity, the formation was lower than in Example 1.
- the new cementum e is also formed from the existing cementum surface to the tooth root surface, but in the middle of the defective cavity. The thickness was reduced toward, and the degree of its formation was lower than that of Example 1.
- Example 2 results indicate that, despite the fact that Example 1 had a greater defect than Comparative Example 1, the results in Example 1 with bFGF shown in SEQ ID NO: 1 were added. Since regeneration or repair of periodontal tissue is remarkably observed, bFGF represented by SEQ ID NO: 1 was obtained from the ruptured periodontal tissue, that is, periodontal ligament. Has a clear promoting effect on regeneration of alveolar bone and cement, etc., and has been shown to be useful in the treatment of periodontal tissue diseases Example 2
- B FGF 1.77 mg / ml represented by SEQ ID NO: 1 in 0.1 M phosphate buffer (pH 6.5), fibrino-gen (Bering 41.6 mg Zm1, aprotinin (manufactured by Beling Berke) 0.41 mg Zm1 and drombin (manufactured by Berke) 33.3 UZm1 and a gelled product was prepared.
- fibrino-gen Bering 41.6 mg Zm1, aprotinin (manufactured by Beling Berke) 0.41 mg Zm1 and drombin (manufactured by Berke) 33.3 UZm1 and a gelled product was prepared.
- the dog was brushed to maintain the state of the tissue in the surrounding tissue for a period of 322 hours by performing brushing, etc., on a hemp-soaked small-and-near-exposure scheme for healthy teeth.
- the general anesthesia with a new barbital natrim (manufactured by Nakarai Tesk Co., Ltd.) was applied to Kishirokine (Fujiroro: 5f Co., Ltd.).
- Kishirokine Friroro: 5f Co., Ltd.
- the fourth premolar of the lower jaw was extracted under fiff sickness, and after 1 month, the extraction cavity was healed, and the lower premolars on both sides where no abnormality was observed in the oral cavity were used as the experimental site.
- the mucoperiosteal flap was peeled off and the bones were exposed under general anesthesia and under anesthesia at the test site.
- a 3 mm X centrifugal width 3 mm X depth 4 mm form was prepared, and the dentin was exposed by removing the cement on the root surface of the tooth with a chisel etc. ⁇ o
- the fibrin gel 28.5 ⁇ 1 containing no bGF shown in SEQ ID NO: 1 was added on the left side (Comparative Example 2), and 50 ig was added on the right side (Example 2).
- the animals were sacrificed 2 and 4 weeks after the operation, and pathological tissue specimens were prepared according to a conventional method and observed with an optical microscope.
- FIGS. 3 and 7 show the optical microscope observation port of the pathological specimen of Example 2, and FIGS. 4 and 6 show the results of optical microscopic observation of the pathological specimen of Comparative Example 2.
- Figures 3 and 4 show the results 2 weeks after the operation.
- Figures 9, 5, 6 and 7 show the results 4 weeks after the operation.
- FIGS. 3 to 6 show the results obtained by staining with matoxylin and eosin at a magnification of 10.times.
- FIG. 7 shows one of the results shown in FIG. The part was enlarged to a magnification of 25 times.
- neoplastic cement e is formed on the root surface, which is bare from the existing cement material surface, and is located in the resorbing fossa of the root dentin. Also, neonatal cementum e was formed almost uniformly, and the thickness was increased compared to neonatal cementum 2 weeks after the operation.
- the new periodontal ligament c was almost the same as that obtained two weeks after the operation in Comparative Example 2.
- the fiber density of the new periodontal ligament c was low, and the fiber bundle was often thin.
- long junctional epithelium h was formed due to invasion of limbal epithelial cells.
- Example 2 Neither root absorption nor agglutination was observed in Example 2 and Comparative Example 2.
- Table 1 shows the results of the obtained tissue observations. The pathological findings were expressed as evaluation scores (classification values) and statistically processed using the Wilcoxon test (one-sided test). As is evident from FIGS. 3 to 7 and Table 1, the promotion effect of bFGF shown in SEQ ID NO: 1 on periodontal tissue regeneration is not significant for alveolar bone regeneration. Two weeks later, it was clearly observed, and the regeneration of periodontal ligament and cementum became more prominent 4 weeks after the operation.
- bFGF has an important effect in the treatment of periodontal tissue diseases, which significantly promotes the improvement of destructed and damaged periodontal tissues.
- bFGF represented by SEQ ID NO: 1.
- the LD5 () value of bFGF shown in SEQ ID NO: 1 by subcutaneous and oral administration to male and female rats was 75 mg / kg or more for all. Met.
- LD 5 Q value of I good that subcutaneous you against the null beauty transdermal administration Ru is shown in SEQ ID NO: 1 that by the b FGF is, its Re respectively 5 your good beauty 3. 3 6 mg / kg or more there were.
- the maximum dose that could be administered to rats and dogs was administered as described above, no fatal cases were found in either sexes. possibility
- the therapeutic agent of the periodontal tissue disease which has the quick regeneration action of the periodontal tissue, and the periodontal tissue disease using the same
- the present invention provides a method for treating dentistry, an implant material fixation promoter, and a remedy for dentin regeneration.
- the periodontal tissue lost due to the progression of periodontitis that is, balm of the entire tissue such as cement, periodontal ligament and alveolar bone.
- Application to regenerative healing with proper maintenance of the condition, as well as restoration and implantation of periodontal tissue after tooth extraction and removal of cysts or oral cancer Provided is a therapeutic agent for periodontal tissue disease which is applied to promote the establishment of wood, regenerate defective dentin by contact, and the like.
- a highly effective treatment method for periodontal tissue diseases with no side effects using the therapeutic agent is established. Arrangement table
- Organism name Homo sapiens sequence
- Organism name Homo sapiens sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU49817/93A AU680204B2 (en) | 1993-08-25 | 1993-08-25 | Periodontal disease remedy |
| US08/325,186 US6046164A (en) | 1993-08-25 | 1993-08-25 | Therapeutic agent for diseases of periodontal tissue |
| CA002147749A CA2147749C (en) | 1993-08-25 | 1993-08-25 | Therapeutic agent for diseases of periodontal tissue |
| KR1019950701568A KR950703993A (ko) | 1993-08-25 | 1993-08-25 | 치주 조직 질환 치료제(periodonal disease remedy) |
| EP93919583A EP0677294A4 (en) | 1993-08-25 | 1993-08-25 | AGAINST PERIODONTAL DISEASES. |
| PCT/JP1993/001211 WO1995005840A1 (en) | 1993-08-25 | 1993-08-25 | Periodontal disease remedy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002147749A CA2147749C (en) | 1993-08-25 | 1993-08-25 | Therapeutic agent for diseases of periodontal tissue |
| PCT/JP1993/001211 WO1995005840A1 (en) | 1993-08-25 | 1993-08-25 | Periodontal disease remedy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1995005840A1 true WO1995005840A1 (en) | 1995-03-02 |
Family
ID=25677917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1993/001211 Ceased WO1995005840A1 (en) | 1993-08-25 | 1993-08-25 | Periodontal disease remedy |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1995005840A1 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003082321A1 (ja) * | 2002-04-01 | 2005-07-28 | 科研製薬株式会社 | 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤 |
| JP2006225398A (ja) * | 2002-04-01 | 2006-08-31 | Kaken Pharmaceut Co Ltd | 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤 |
| WO2008087862A1 (ja) * | 2007-01-18 | 2008-07-24 | Regenetiss Inc. | 抗歯周病剤 |
| JPWO2010007651A1 (ja) * | 2008-07-15 | 2012-01-05 | リジェンティス株式会社 | 抗歯周病効果を有する組成物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354328A (ja) * | 1986-04-23 | 1988-03-08 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 創傷治癒組成物およびそれを用いた創傷包帯 |
| JPS63226287A (ja) * | 1986-03-14 | 1988-09-20 | Takeda Chem Ind Ltd | ポリペプチド,dnaおよびその用途 |
| JPH05124975A (ja) * | 1990-12-19 | 1993-05-21 | Kaken Pharmaceut Co Ltd | 骨疾患治療剤 |
| JPH05132426A (ja) * | 1991-02-15 | 1993-05-28 | Takeda Chem Ind Ltd | 骨組織の形成促進剤 |
-
1993
- 1993-08-25 WO PCT/JP1993/001211 patent/WO1995005840A1/ja not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63226287A (ja) * | 1986-03-14 | 1988-09-20 | Takeda Chem Ind Ltd | ポリペプチド,dnaおよびその用途 |
| JPS6354328A (ja) * | 1986-04-23 | 1988-03-08 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 創傷治癒組成物およびそれを用いた創傷包帯 |
| JPH05124975A (ja) * | 1990-12-19 | 1993-05-21 | Kaken Pharmaceut Co Ltd | 骨疾患治療剤 |
| JPH05132426A (ja) * | 1991-02-15 | 1993-05-28 | Takeda Chem Ind Ltd | 骨組織の形成促進剤 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0677294A4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003082321A1 (ja) * | 2002-04-01 | 2005-07-28 | 科研製薬株式会社 | 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤 |
| JP2006225398A (ja) * | 2002-04-01 | 2006-08-31 | Kaken Pharmaceut Co Ltd | 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤 |
| WO2008087862A1 (ja) * | 2007-01-18 | 2008-07-24 | Regenetiss Inc. | 抗歯周病剤 |
| JPWO2010007651A1 (ja) * | 2008-07-15 | 2012-01-05 | リジェンティス株式会社 | 抗歯周病効果を有する組成物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Berglundh et al. | The topography of the vascular systems in the periodontal and peri‐implant tissues in the dog | |
| CN1034630C (zh) | 促结合组合物的制备方法 | |
| Yaffe et al. | Restoration of periodontal attachment employing enriched collagen solution in the dog | |
| WO2009144708A1 (en) | Augmentation and treatment of gingival defects | |
| JP2550360B2 (ja) | 結合誘発性組成物 | |
| Heithersay | Replantation of avulsed teeth. A review | |
| D'Elia et al. | Peri-implant Soft Tissue Stability After Single Implant Restorations Using Either Guided Bone Regeneration or a Connective Tissue Graft: A Randomized Clinical Trial. | |
| Nilvféus et al. | The effect of autogenous cancellous bone grafts on gealing of experimental furcation defects in dogs | |
| JPH11501029A (ja) | モルフォゲン誘導性ぞうげ質再生 | |
| Kim et al. | Preclinical investigation on the effect of collagen matrix with polydeoxyribonucleotide at buccally positioned implants | |
| US10016492B2 (en) | Methods for extracting a tooth | |
| JP3594976B2 (ja) | 歯周疾患治療剤 | |
| US6046164A (en) | Therapeutic agent for diseases of periodontal tissue | |
| KR20190087835A (ko) | Cpne7의 치주인대 재생 용도 | |
| JP2008526871A (ja) | 歯周および歯の治療のためのペプチド製剤 | |
| Tuttle et al. | Platelet-rich fibrin minimally invasive root recession soft-tissue grafting | |
| Neckel | Vestibuloplasty: a retrospective study on conventional and laser operation techniques | |
| CA2147749C (en) | Therapeutic agent for diseases of periodontal tissue | |
| KR102913837B1 (ko) | 치주염 치료 및 치간 유두 재생용 조성물 | |
| Zucchelli | Long-term maintenance of an apparently hopeless tooth: a case report. | |
| Ellender et al. | Osteogenic capacity of collagen in repair of established periodontal defects | |
| Mouzinho | Treatment of Denture Induced Fibrous Hyperplasia with Carbon Dioxide Laser | |
| Ganesh et al. | Combined Resective and Regenerative Therapy-A Novel Approach in the Management of Furcation Involvement: A Case Report | |
| JPWO1995005840A1 (ja) | 歯周組織疾患治療剤 | |
| Lambert et al. | Free autogenous graft coverage of vital retained roots |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2147749 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993919583 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 08325186 Country of ref document: US |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 1993919583 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993919583 Country of ref document: EP |